Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This article reviews the medical history and symptoms related to hyperandrogenism in patients, but reports no new clinical findings.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This article reviews evidence on hyperinsulinemia and insulin resistance in women with polycystic ovary syndrome and evaluates therapeutic responses to insulin-lowering agents, reporting no new clinical findings.

This article discusses the mechanisms of hirsutism and acne in women, highlighting cyproterone acetate with ethinyloestradiol as an effective anti-androgen therapy in the UK, but it reports no new clinical findings.

This study aimed to describe the distribution of eyebrow and eyelash hair loss in patients with varying severities of scalp hair loss from alopecia areata but does not report results.

Hormonal contraceptives and related compounds can increase health risks like thrombosis and affect sexual function.

This article discusses treatments for hirsutism and acne in women with polycystic ovary syndrome, suggesting that lower doses of current medications maintain efficacy while reducing cost and side effects, but reports no new clinical results.

This study suggests that the progesterone metabolite allopregnanolone and progesterone regulate distinct gene sets involved in glioblastoma cell proliferation, with some overlapping effects modified by finasteride.

This review highlights that pharmacologic therapy for hirsutism can effectively decrease hair growth, normalize menstrual cycles, and reduce endometrial cancer risk, with improvements in physical and mental well-being and minimal serious side effects reported.

This review examines current evidence on personalized management strategies for PCOS, but does not present new clinical results; the authors advocate for treatments tailored to predominant symptoms and individual health profiles.

This study found that feeding norethindrone acetate to albino rats over two years caused various dose-related health effects, such as growth retardation and liver changes, but did not increase overall tumor incidence.

This study concluded that clomiphene citrate is generally preferred over metformin for inducing ovulation in obese women with PCOS, despite low-quality evidence indicating metformin may be superior to placebo for live births.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

This review examines the best available evidence for diagnosing and managing PCOS but reports no new clinical results.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

This review highlights the low uptake of tamoxifen and finasteride for cancer chemoprevention in primary care, citing various barriers and indicating a need for safer, more affordable options.

This retrospective study found that cyproterone acetate, both alone and with estrogens, was safe, well tolerated, and induced modest feminizing effects in late-pubertal transgender female adolescents.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.

This study found that the extracts of Serenoa repens, when evaluated through chemical, biological, and in silico methods, demonstrated anti-inflammatory, pro-apoptotic, and anti-androgenic activities against prostate cancer cell lines, suggesting potential therapeutic benefits and directing future pharmaceutical development.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

In this study, finasteride inhibited progesterone synthesis in mouse-derived MA-10 Leydig tumor cells by blocking cholesterol side-chain cleavage, but human and rat cells showed minimal sensitivity.

This study found that compliance rates for oral contraceptives are low and similar to those for other medical treatments, indicating a need for alternatives that require less daily adherence.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.